The Latest News
Valeritas Inc. Selects dLife's New Diabetes Patient Engagement Solution For Valeritas' V-go Disposable Insulin Delivery Device>
Valeritas has selected dLife to support its state-of-the-art patient engagement program. dLife, the number-one resource and community network for people living with diabetes, and Valeritas have co-developed V-Go Life, a comprehensive diabetes lifestyle management and support program designed to increase engagement of V-Go users.
With its innovative and simple-to-use insulin delivery device, the V-Go™, Valeritas knows the importance of easy-to-use delivery mechanisms. Its CRM system is no exception. The medical technology company desperately wanted to replace its convoluted, problematic client/server CRM system with something more straightforward to deliver valuable physician information to its commercial teams and vice versa more efficiently. Valeritas turned to cloud-based Veeva CRM and Veeva iRep for the iPad, the same system used by its valued contract sales partner, inVentiv.
Estech Announces FDA Approval to begin Enrollment in ATTAC-AF IDE Trial for the Treatment of Atrial Fibrillation during Cardiac Surgery>
Estech, a leader in minimally invasive and endoscopic cardiac ablation, announced today that the Food and Drug Administration (FDA) has given conditional Investigational Device Exemption (IDE) approval to initiate patient enrollment in the Estech-sponsored ATTAC-AF trial.
Synageva BioPharma and Mitsubishi Tanabe Pharma Corporation Expand Development Collaboration with Second Program>
Synageva BioPharma Corp. (“Synageva”) announced today an expansion of its previous collaboration with Mitsubishi Tanabe Pharma Corporation (Head Office; Osaka, Japan, “MTPC”) to develop a second protein therapeutic for an undisclosed orphan disease using Synageva’s product development capabilities and proprietary protein expression platform.
Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA) today reported 2011 full year financial results and provided 2012 financial guidance. “Strengthened balance sheet enables a focus on key objectives--Adult LAL Deficiency patients continue to enroll into extension study”.
SupplyPro today announced that Graybar has become an approved reseller of the SupplyPro vending solutions. Graybar, a leading distributor of electrical, communications and data networking products and provider of related supply chain management and logistics services, is dedicating sales and marketing resources to establish a vending program to serve the needs of its client-base.
Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), today announced that it will be presenting at the upcoming Cowen and Company 32nd Annual Healthcare Conference. Sanj K. Patel, President and Chief Executive Officer of Synageva, is scheduled to present on Tuesday, March 6, 2012, at 9:20 AM Eastern Standard Time.
Estech Announces Start of Patient Enrollment in HISTORIC-AF European Multi-center Staged Hybrid Ablation Study>
Estech, a leader in minimally invasive cardiac surgery, announced today that the first three patients have been enrolled in the HISTORICAF European multi-center staged hybrid ablation clinical study. Ten centers will participate in the study which is expected to enroll over 100 patients in Italy, Germany, the United Kingdom, France, and Poland.
Synageva BioPharma Corp., a clinical stage biopharmaceutical company developing therapeutic products for rare disorders has announced that following the special meeting of shareholders on November 2, 2011, the Synageva and Trimeris, Inc. merger has closed.
New SupplyPro Distributor Command Center Provides Anytime-Anywhere Data Access and Materials Visibility Across All Customers and Locations Using Point-of-Use Technologies>
New SupplyPro Distributor Command Center Provides Anytime-Anywhere Data Access and Materials Visibility Across All Customers and Locations Using Point-of-Use Technologies
Vidacare— Vascular Access Using Intraosseous (Inside the Bone) Space Less Expensive and Equally Effective Compared to Central Venous Catheters in Hospital Setting>
Vidacare— Vascular Access Using Intraosseous (Inside the Bone) Space Less Expensive and Equally Effective Compared to Central Venous Catheters in Hospital Setting
Impulse Monitoring, Inc. (IMI) today announced that the agreement to be acquired by NuVasive, Inc. (Nasdaq: “NUVA”), had closed. Going forward, IMI will continue to exclusively provide neuromonitoring services as an independent subsidiary of a larger organization.